| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Vir Biotechnology, Inc.
13D/A
VIR · 92764N102
|
7.3% |
11/6/2026
Event 11/4/2026
|
||||
| ARCH Venture Fund IX, L.P. | 6.9% | |||||
| ARCH Venture Fund IX Overage, L.P. | 6.9% | |||||
| ARCH Venture Partners IX, L.P. | 6.9% | |||||
| ARCH Venture Partners IX Overage, L.P. | 6.9% | |||||
| ARCH Venture Partners IX, LLC | 6.9% | |||||
| Robert Nelsen | 7.3% | |||||
| Keith Crandell | 7.1% | |||||
| Clinton Bybee | 7.0% | |||||
| Schedule 13G · 5 securities · passive | ||||||
|
Sana Biotechnology, Inc.
13G/A
SANA · 799566104
|
15.4% |
8/14/2026
Event 6/30/2026
|
||||
| ARCH Venture Fund IX, L.P. | 15.3% | |||||
| ARCH Venture Fund IX Overage, L.P. | 15.3% | |||||
| ARCH Venture Fund X, L.P. | 15.3% | |||||
| ARCH Venture Fund X Overage, L.P. | 15.3% | |||||
| ARCH Venture Partners IX, L.P. | 15.3% | |||||
| ARCH Venture Partners IX Overage, L.P. | 15.3% | |||||
| ARCH Venture Partners X Overage, L.P. | 15.3% | |||||
| ARCH Venture Partners X, L.P. | 15.3% | |||||
| ARCH Venture Partners IX, LLC | 15.3% | |||||
| ARCH Venture Partners X, LLC | 15.3% | |||||
| Keith Crandell | 15.3% | |||||
| Clinton Bybee | 15.3% | |||||
| Robert Nelsen | 15.4% | |||||
| Steven Gillis | 15.3% | |||||
| Kristina Burow | 15.3% | |||||
|
Lyell Immunopharma, Inc.
13G/A
LYEL · 55083R203
|
13.9% |
5/15/2026
Event 3/31/2026
|
||||
| ARCH Venture Fund IX, L.P. | 13.9% | |||||
| ARCH Venture Fund IX Overage, L.P. | 13.9% | |||||
| ARCH Venture Fund XIII, L.P. | 13.9% | |||||
| ARCH Venture Partners IX, L.P. | 13.9% | |||||
| ARCH Venture Partners IX Overage, L.P. | 13.9% | |||||
| ARCH Venture Partners IX, LLC | 13.9% | |||||
| ARCH Venture Partners XIII, L.P. | 13.9% | |||||
| ARCH Venture Partners XIII, LLC | 13.9% | |||||
| Keith Crandell | 13.9% | |||||
| Clinton Bybee | 7.8% | |||||
| Robert Nelsen | 13.9% | |||||
| Kristina Burow | 13.9% | |||||
| Steven Gillis | 13.9% | |||||
| Paul Berns | 6.1% | |||||
|
Singular Genomics Systems, Inc.
13G/A
OMIC · 82933R308
|
0% |
5/15/2025
Event 2/21/2025
|
||||
| ARCH Venture Fund IX, L.P. | 0% | |||||
| ARCH Venture Partners IX, L.P. | 0% | |||||
| ARCH Venture Partners IX, LLC | 0% | |||||
| Keith Crandell | 0% | |||||
| Clinton Bybee | 0% | |||||
| Robert Nelsen | 0% | |||||
|
Beam Therapeutics Inc.
13G/A
BEAM · 07373V105
|
4.6% |
5/15/2025
Event 3/31/2025
|
||||
| ARCH Venture Fund IX, L.P. | 4.5% | |||||
| ARCH Venture Fund IX Overage, L.P. | 4.5% | |||||
| ARCH Venture Partners IX, L.P. | 4.5% | |||||
| ARCH Venture Partners IX Overage, L.P. | 4.5% | |||||
| ARCH Venture Partners IX, LLC | 4.5% | |||||
| Keith Crandell | 4.5% | |||||
| Clinton Bybee | 4.5% | |||||
| Robert Nelsen | 4.6% | |||||
|
Lyell Immunopharma, Inc.
13G/A
LYEL · 55083R104
|
13.1% |
2/14/2025
Event 12/31/2024
|
||||
| ARCH Venture Fund IX, L.P. | 13.0% | |||||
| ARCH Venture Fund IX Overage, L.P. | 13.0% | |||||
| ARCH Venture Partners IX, L.P. | 13.0% | |||||
| ARCH Venture Partners IX Overage, L.P. | 13.0% | |||||
| ARCH Venture Partners IX, LLC | 13.0% | |||||
| Keith Crandell | 13.0% | |||||
| Clinton Bybee | 13.0% | |||||
| Robert Nelsen | 13.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.